Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B

Jazz Pharmaceuticals plc

2024-FY EPS reported $8.65 revenue$4,068,950,000

Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.
GAAP diluted EPS $8.65 (FY2024) vs $6.10 (FY2023); Non-GAAP diluted EPS $20.90 vs $18.29.
Xywav+Epidiolex grew 16% and 15% YoY; oncology revenue surpassed $1.1B (+9%).
2025 guidance: total revenue $4.15-4.40B; GAAP EPS $9.15-11.50; Non-GAAP EPS $22.50-24.00.
Cash from ops $1.4B; voluntary $750M debt prepayment in Jan 2025; Ziihera launch initial sales $1.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.